DTIL
Precision BioSciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.47
+1.36%Next report
Analyst consensus
- Next report date
- Nov 2, 2026
- EPS estimate
- -$0.85
- Revenue estimate
- $1.1M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$1.26
- EPS estimate
- -$0.80
- Revenue actual
- —
- Revenue estimate
- $740.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -690.8%
- Revenue beats (12Q)
- 4
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $40
- PT range
- $20 – $60
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 2, 2026